Antoine Yver - Dec 31, 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
EVP & Chairman of Development
Signature
/s/ Gregory Weinhoff, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Dec 31, 2022
Transactions value $
-$29,167
Form type
4
Date filed
1/4/2023, 06:30 PM
Previous filing
Dec 5, 2022
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Tax liability -$7.03K -2.27K -0.3% $3.10 759K Dec 31, 2022 Direct F1, F2
transaction CNTA Ordinary Shares Sale -$22.1K -6.97K -0.92% $3.18 752K Jan 4, 2023 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
F3 The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted shares. These sales were automatic and intended to qualify under Rule 10b5-1.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.